NO870027L - Ekspresjon av htlv-iii gag-gen. - Google Patents
Ekspresjon av htlv-iii gag-gen.Info
- Publication number
- NO870027L NO870027L NO870027A NO870027A NO870027L NO 870027 L NO870027 L NO 870027L NO 870027 A NO870027 A NO 870027A NO 870027 A NO870027 A NO 870027A NO 870027 L NO870027 L NO 870027L
- Authority
- NO
- Norway
- Prior art keywords
- polypeptide
- gene
- fragment
- gag
- htlv
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 150
- 102000004169 proteins and genes Human genes 0.000 claims description 95
- 101710177291 Gag polyprotein Proteins 0.000 claims description 75
- 101710125418 Major capsid protein Proteins 0.000 claims description 72
- 208000030507 AIDS Diseases 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 229920001184 polypeptide Polymers 0.000 claims description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 29
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 27
- 230000002797 proteolythic effect Effects 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 239000002243 precursor Substances 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 11
- 210000005253 yeast cell Anatomy 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 claims 2
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 88
- 239000013612 plasmid Substances 0.000 description 37
- 108700004026 gag Genes Proteins 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 27
- 101150098622 gag gene Proteins 0.000 description 27
- 241000700605 Viruses Species 0.000 description 23
- 239000006166 lysate Substances 0.000 description 19
- 239000002609 medium Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000017854 proteolysis Effects 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 108700004029 pol Genes Proteins 0.000 description 8
- 101150088264 pol gene Proteins 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000013198 immunometric assay Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 150000002972 pentoses Chemical class 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- -1 GALI Proteins 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000000652 homosexual effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000714195 Aids-associated retrovirus Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001213911 Avian retroviruses Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 229930182818 D-methionine Natural products 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 description 1
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 description 1
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 description 1
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101710142250 Protein p56 Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101710167911 Repressible acid phosphatase Proteins 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 101710085459 p48 protein Proteins 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81664586A | 1986-01-06 | 1986-01-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO870027D0 NO870027D0 (no) | 1987-01-05 |
| NO870027L true NO870027L (no) | 1987-07-07 |
Family
ID=25221244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO870027A NO870027L (no) | 1986-01-06 | 1987-01-05 | Ekspresjon av htlv-iii gag-gen. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0230222A1 (da) |
| JP (1) | JPS62164696A (da) |
| AU (1) | AU6713287A (da) |
| DK (1) | DK3687A (da) |
| NO (1) | NO870027L (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0220234B1 (en) * | 1985-04-08 | 1994-08-03 | Genetic Systems Corporation | EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV |
| FR2625100A2 (fr) * | 1986-03-13 | 1989-06-30 | Lurhuma Zirimwabagabo | Utilisation d'antigenes pour la preparation de vaccins, proteine rendue immunogene et composition pharmaceutique la comportant |
| US5075211A (en) * | 1986-03-26 | 1991-12-24 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
| US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
| US4983387A (en) * | 1986-05-19 | 1991-01-08 | Viral Technologies Inc. | HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus |
| DK643188A (da) * | 1987-11-24 | 1989-05-25 | Smithkline Biolog | Ekspression af hiv-proteiner i e.coli og s.cerevisiae |
| JPH01148183A (ja) * | 1987-12-04 | 1989-06-09 | Hiroshi Shibuta | 組み換えワクチニアウイルス |
| IL90048A0 (en) * | 1988-04-25 | 1989-12-15 | Merck & Co Inc | Recombinant gag precursor of hiv,its preparation and its use as aids vaccine |
| IL89993A0 (en) * | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of the hiv 24kda gag protein in methylotrophic yeasts |
| AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| FR2632310B1 (fr) * | 1988-06-06 | 1992-04-10 | Pasteur Institut | Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles |
| ATE134195T1 (de) * | 1988-06-10 | 1996-02-15 | United Biomedical Inc | Peptidfragmente von hiv |
| EP0352060A3 (en) * | 1988-07-21 | 1990-12-27 | Takeda Chemical Industries, Ltd. | Expression plasmid and use thereof |
| US5219725A (en) | 1988-12-05 | 1993-06-15 | Idexx Laboratories Incorporated | Monoclonal antibodies to feline-t-lymphotropic lentivirus |
| EP0860504A1 (en) * | 1989-05-08 | 1998-08-26 | Idexx Laboratories, Inc. | Polypeptides of feline T-cell lymphotropic lentivirus |
| JPH03128393A (ja) * | 1989-05-17 | 1991-05-31 | Sangstat Medical Corp | ヒトリンパ栄養性ウィルスの処理及び診断 |
| GB8918200D0 (en) * | 1989-08-09 | 1989-09-20 | Medical Res Council | The peptide fragments of hiv |
| IL95738A (en) * | 1989-09-23 | 1996-11-14 | Hoechst Ag | Antibodies against the well-preserved amino acid sequences of insulin, a process for their preparation and use in immunoassay |
| NZ235538A (en) * | 1989-10-12 | 1992-06-25 | Viral Technologies Inc | Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera |
| WO1991009869A1 (en) * | 1990-01-05 | 1991-07-11 | Medical Research Council | Hiv-1 core protein fragments |
| WO1991018990A1 (en) * | 1990-05-28 | 1991-12-12 | The Research Foundation For Microbial Diseases Of Osaka University | Method of preparing plasmid having capabilities of expressing and processing after translation of retrovirus gene, plasmid obtained thereby and product of expression thereof |
| AU8849391A (en) * | 1990-08-16 | 1992-03-17 | Diagnostic Biotechnology, Inc. | An augmented western blot format and immunoassay for detection of viral antibodies |
| ES2171454T3 (es) | 1993-06-04 | 2002-09-16 | Whitehead Biomedical Inst | Proteinas de estres y sus usos. |
| WO1998029551A1 (en) * | 1997-01-02 | 1998-07-09 | Universidade Federal De Minas Gerais | THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN HYBRID PROTEIN (p24/p17) DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUSES (HIV-1) |
| WO1999012416A1 (en) * | 1997-09-09 | 1999-03-18 | The Trustees Of Columbia University In The City Of New York | T-independent conjugate-vaccines |
| US5972339A (en) * | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
| NO311807B1 (no) | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| US6964851B2 (en) | 1999-12-07 | 2005-11-15 | Stressgen Biotechnologies Corp. | Compositions and methods for detecting stress-inducible proteins |
| AU1814101A (en) | 2000-01-14 | 2001-07-24 | Massachusetts Institute Of Technology | In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent |
| SK18362002A3 (sk) | 2000-06-26 | 2004-02-03 | Stressgen Biotechnologies Corporation | Použitie prostriedku s obsahom fúzneho proteínu |
| JP2015520179A (ja) | 2012-06-06 | 2015-07-16 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | ワクチン |
| WO2016005508A1 (en) | 2014-07-11 | 2016-01-14 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341482C (en) * | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
| DE3588134T2 (de) * | 1984-12-24 | 1997-03-20 | Genentech Inc | Fusionen von AIDS-verwandten Polypeptiden |
-
1987
- 1987-01-05 EP EP87100064A patent/EP0230222A1/en not_active Withdrawn
- 1987-01-05 DK DK003687A patent/DK3687A/da not_active Application Discontinuation
- 1987-01-05 AU AU67132/87A patent/AU6713287A/en not_active Abandoned
- 1987-01-05 NO NO870027A patent/NO870027L/no unknown
- 1987-01-05 JP JP62000334A patent/JPS62164696A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62164696A (ja) | 1987-07-21 |
| NO870027D0 (no) | 1987-01-05 |
| EP0230222A1 (en) | 1987-07-29 |
| AU6713287A (en) | 1987-07-09 |
| DK3687D0 (da) | 1987-01-05 |
| DK3687A (da) | 1987-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO870027L (no) | Ekspresjon av htlv-iii gag-gen. | |
| EP0199301B2 (en) | Recombinant acquired immune deficiency syndrome (AIDS) viral envelope protein fragments and method of testing for AIDS | |
| Yamashiro et al. | Phosphorylation of non-muscle caldesmon by p34 cdc2 kinase during mitosis | |
| US5677143A (en) | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids | |
| US5141867A (en) | Nucleotide sequence encoding a human immunodeficiency virus antigen | |
| US4861707A (en) | Human immunodeficiency virus antigen | |
| DK172274B1 (da) | HTLV-III-virusprotein, DNA-sekvens, der koder herfor, fremgangsmåde til fremstilling heraf, fremgangsmåde til detektion af AIDS-virus samt antistoffer mod AIDS-virus | |
| EP0258404B1 (en) | Method of detecting antibody against htlv-iii | |
| US5221610A (en) | Diagnostic method and composition for early detection of HIV infection | |
| US4784941A (en) | Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV | |
| EP0436634A1 (en) | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids | |
| JP2637278B2 (ja) | Ｈｔｌｖ―▲ｉ▼の合成エンベロープペプチド | |
| KR960005181B1 (ko) | 재조합 htlv-ⅲ 단백질 및 이의 용도 | |
| NZ225833A (en) | Hiv proteins and peptides, immunoassay and vaccines | |
| EP0453563A1 (en) | Diagnostic proteins to test for more than one antibody | |
| EP0345792A2 (en) | HTLV-I / HIV-1 fusion proteins | |
| US5134227A (en) | DNA encoding immunoreactive, chimeric HTLV-III GAG proteins | |
| US5773210A (en) | Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS | |
| KR910000748B1 (ko) | 사람 면역결핍증 바이러스의 gag-암호화된 단백질 | |
| MARCUS-SEKURA et al. | Expression of HIV-1 integrase in E. coli: immunological analysis of the recombinant protein | |
| WO1998052970A1 (en) | Vif-derived hiv protease inhibitors | |
| EP0235923B1 (en) | Sor gene product from human t-cell lymphotropic virus iii | |
| CA2017936A1 (en) | Htlv-1 env gene products expressed in e. coli | |
| Kreusel et al. | Mouse monoclonal antibodies recognizing the activation domains of HIV-1 rev transactivator | |
| WO1996012023A1 (en) | A recombinant protein designated dev-1, useful in the detection of hiv, dna sequence encoding the protein, and immunoassays using the protein |